19-05-2021 | 15:35 PM
2-deoxy-D-glucose (2-DG) Drug
• The Drug Controller General of India (DCGI) has approved the emergency use of 2-deoxy-D-glucose (2-DG) as additive therapy for moderate to severe COVID-19 patients.
• The anti-COVID-19 drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
Key Points:
• The drug ensures faster recovery of hospitalized patients and will reduce supplemental oxygen dependence during clinical trials.
• The clinical trials have shown that 2-deoxy-D-glucose (2-DG) helps in faster recovery of hospitalized patients and reduces dependence on supplemental oxygen.
